MITRA.BR Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 18:35):

Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Europe and internationally...

Stats
Šios dienos apimtis	82 336.00
Vidutinė apimtis	387 170
Rinkos kapitalizacija	14.93M
EPS	€0 ( 2024-03-08 )
Kita pelno data	( €0 ) 2024-05-30
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-0.150
ATR14	€0.00100 (0.46%)

Mithra Pharmaceuticals SA Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Mithra Pharmaceuticals SA Finansinės ataskaitos

Annual	2023
Pajamos:	€40.16M
Bruto pelnas:	€5.99M (14.92 %)
EPS:	€-2.51

FY	2023
Pajamos:	€40.16M
Bruto pelnas:	€5.99M (14.92 %)
EPS:	€-2.51

FY	2022
Pajamos:	€67.00M
Bruto pelnas:	€35.43M (52.89 %)
EPS:	€-1.220

FY	2021
Pajamos:	€22.67M
Bruto pelnas:	€6.94M (30.63 %)
EPS:	€-1.114

Financial Reports:

No articles found.

Mithra Pharmaceuticals SA

Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Europe and internationally. Its development candidates include Estelle, which has completed phase III clinical trial, which is a combined oral contraceptive; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a solution for treating menopause and osteoporosis; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications. In addition, it offers NEXTSTELLIS, an oral contraceptive pill. In addition, the company provides products in polymeric forms, implants, sterile injectable products, and hormonal tablets. Mithra Pharmaceuticals SA was founded in 1999 and is headquartered in Liège, Belgium.